Dr Stuart Hannah is a health technology entrepreneur on a mission to transform the lives of patients globally by developing rapid diagnostic tests to tackle antimicrobial resistance. He co-founded Microplate Dx with the vision to become the leading provider of platform diagnostics to tackle the major global healthcare challenge of antimicrobial resistance in a rapid, scalable and inclusive manner. Dr Hannah has a PhD in Electronic & Electrical Engineering from the University of Strathclyde in Glasgow, Scotland, and has 10+ years’ academic and industrial experience in developing biosensors and diagnostics for healthcare. Since forming the company in 2021 and undertaking a prestigious Royal Society of Edinburgh Enterprise Fellowship, Stuart has already raised over £3m in equity investment, won numerous awards, and has grown the highly-experienced Microplate Dx team to 14 members. Microplate Dx’s first product is targeting urinary tract infections which are worryingly the cause of 1 in 4 sepsis presentations. The AI-driven platform diagnostic test enables rapid infection detection and treatment, by ensuring the right antibiotic is prescribed to patients in a matter of minutes (vs gold standard treatments which can take >2 days) and has widespread applicability across primary/secondary healthcare settings across the world. Away from work, Stuart’s main interests include walking, reading, and current affairs.